BRIEF-Dr David Stamler Appointed CEO
- ByReuters
- •
Alterity Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes. ATH434 has been granted Orphan Drug designation for the treatment of Multiple System Atrophy.